Evidence map›Paper›PMID 30045764›Full record

ArticleTrials2018

The use of a risk assessment and decision support tool (CRISP) compared with usual care in general practice to increase risk-stratified colorectal cancer screening: study protocol for a randomised controlled trial.

Jennifer G Walker, Finlay Macrae, Ingrid Winship, Jasmeen Oberoi, Sibel Saya, Shakira Milton, Adrian Bickerstaffe, James G Dowty, Richard De Abreu Lourenço, Malcolm Clark and 10 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Polygenic scores in cancer.Nature reviews. Cancer · 2023
    Review
  5. Article
  6. Acceptability of risk-stratified population screening across cancer types: Qualitative interviews with the Australian public.Health expectations : an international journal of public participation in health care and health policy · 2021
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Jennifer G WalkerCentre for Cancer Research, Department of General Practice, Victorian Comprehensive Cancer Centre, The University of Melbourne, Carlton, VIC, Australia. walker@unimelb.edu.au.ORCID http://orcid.org/0000-0002-6655-0940
Finlay MacraeDepartment of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
Ingrid WinshipDepartment of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
Jasmeen OberoiCentre for Cancer Research, Department of General Practice, Victorian Comprehensive Cancer Centre, The University of Melbourne, Carlton, VIC, Australia.
Sibel SayaCentre for Cancer Research, Department of General Practice, Victorian Comprehensive Cancer Centre, The University of Melbourne, Carlton, VIC, Australia.
Shakira MiltonCentre for Cancer Research, Department of General Practice, Victorian Comprehensive Cancer Centre, The University of Melbourne, Carlton, VIC, Australia.
Adrian BickerstaffeCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
James G DowtyCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Richard De Abreu LourençoCentre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, NSW, Australia.
Malcolm ClarkCentre for Cancer Research, Department of General Practice, Victorian Comprehensive Cancer Centre, The University of Melbourne, Carlton, VIC, Australia.
Louise GallowayDepartment of Health and Human Services, Victorian Government, Melbourne, VIC, Australia.
George FishmanJoint Consumer Advisory Group, Primary Care Collaborative Cancer Clinical Trials Group, Carlton, Australia.
Fiona M WalterCentre for Cancer Research, Department of General Practice, Victorian Comprehensive Cancer Centre, The University of Melbourne, Carlton, VIC, Australia.
Louisa FlanderCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Patty ChondrosDepartment of General Practice, The University of Melbourne, Melbourne, VIC, Australia.
Driss Ait OuakrimCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Marie PirottaCentre for Cancer Research, Department of General Practice, Victorian Comprehensive Cancer Centre, The University of Melbourne, Carlton, VIC, Australia.
Lyndal TrevenaSchool of Public Health, The University of Sydney, Sydney, NSW, Australia.
Mark A JenkinsCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Jon D EmeryCentre for Cancer Research, Department of General Practice, Victorian Comprehensive Cancer Centre, The University of Melbourne, Carlton, VIC, Australia.
The University of Melbourne · AUThe Royal Melbourne Hospital · AUGovernment of Victoria · AUPrimary Care Collaborative Clinical Trials Group · AUThe University of Sydney · AUUniversity of Technology Sydney · AU

Funding

National Health and Medical Research Council APP1042021National Health and Medical Research Council APP1121104Victorian Cancer Agency HSR15019
6 · The paper itself

Abstract

backgroundAustralia and New Zealand have the highest incidence rates of colorectal cancer worldwide. In Australia there is significant unwarranted variation in colorectal cancer screening due to low uptake of the immunochemical faecal occult blood test, poor identification of individuals at increased risk of colorectal cancer, and over-referral of individuals at average risk for colonoscopy. Our pre-trial research has developed a novel Colorectal cancer RISk Prediction (CRISP) tool, which could be used to implement precision screening in primary care. This paper describes the protocol for a phase II multi-site individually randomised controlled trial of the CRISP tool in primary care.

methodsThis trial aims to test whether a standardised consultation using the CRISP tool in general practice (the CRISP intervention) increases risk-appropriate colorectal cancer screening compared to control participants who receive standardised information on cancer prevention. Patients between 50 and 74 years old, attending an appointment with their general practitioner for any reason, will be invited into the trial. A total of 732 participants will be randomised to intervention or control arms using a computer-generated allocation sequence stratified by general practice. The primary outcome (risk-appropriate screening at 12 months) will be measured using baseline data for colorectal cancer risk and objective health service data to measure screening behaviour. Secondary outcomes will include participant cancer risk perception, anxiety, cancer worry, screening intentions and health service utilisation measured at 1, 6 and 12 months post randomisation. DISCUSSION: This trial tests a systematic approach to implementing risk-stratified colorectal cancer screening in primary care, based on an individual's absolute risk, using a state-of-the-art risk assessment tool. Trial results will be reported in 2020.

trial registrationAustralian and New Zealand Clinical Trial Registry, ACTRN12616001573448p . Registered on 14 November 2016.

Indexed as

Decision Support TechniquesGeneral PracticePrimary Health CareAgedClinical Trials, Phase II as TopicColorectal NeoplasmsEarly Detection of CancerFemaleHumansMaleMiddle AgedMulticenter Studies as TopicPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicRisk AssessmentColorectal cancer screeningDecision supportFaecal occult blood testGeneral practicePrecision medicinePrecision screeningPrimary careRisk assessment toolRisk-stratified screening

Identifiers

PMID30045764
PMCPMC6060496
OpenAlexW2884095710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.